LEVELS – A Whole New Level #226 - How do weight-loss medications affect metabolic health? And will Ozempic and other GLP-1s actually solve the obesity crisis? | Dr. Rob Lustig & Dr. Casey Means
Aug 17, 2023
Dr. Rob Lustig and Dr. Casey Means discuss weight-loss medications like Ozempic and how they affect metabolic health. They delve into the mechanisms of action for these drugs, their potential benefits and limitations, and the high cost associated with them. The podcast also addresses the need to address the food industry's role in the obesity crisis, concerns about using these medications in children, and the importance of individualized treatment. Additionally, they discuss the impact of tracking glucose levels, optimizing metabolic health, and the importance of education and support for long-term success in weight loss.
AI Snips
Chapters
Transcript
Episode notes
From Gila Monster To Wegovy
- Semaglutide came after earlier GLP‑1 drugs derived from Gila monster peptides like exenatide (Byetta).
- Novo Nordisk increased dose to create Wegovy for weight loss after observing modest weight effects with Ozempic.
The Economic Band‑Aid Problem
- Universal GLP‑1 coverage would be hugely expensive — roughly $2.1 trillion/year if everyone qualified took it.
- Fixing population sugar intake would cost far less and improve metabolic health more effectively.
Starvation‑Like State And Side Effects
- GLP‑1 treatment creates a different problem: medically induced starvation with side effects like nausea and GI dysfunction.
- One third of patients stop the drugs quickly due to side effects rather than cost.